BridgeBio Oncology Therapeutics (BBOT) Stock Price, News & Analysis

Company Overview

BridgeBio Oncology Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for patients with genetically driven cancers. The company is part of the broader BridgeBio platform, which supports the development of therapies for diseases linked to well-defined biological targets.

Its oncology programs are centered on small-molecule therapies intended to address cancer-causing genetic alterations, including targets that have historically been difficult to treat. BridgeBio Oncology Therapeutics is advancing its pipeline through preclinical research and clinical development, with the goal of providing targeted treatment options for patients with limited alternatives.

The company’s operations are focused on drug discovery and development rather than commercialized products, and its therapies remain subject to clinical testing and regulatory review. Information about its specific commercial reach and leadership is limited; the company’s principal activities are conducted through its oncology research and development programs.

Key Stats

• Today's Range: $2.51 to $2.73
• 50-Day Range: $2.64 to $9.60
• 52-Week Range: $2.51 to $14.87
• Volume: 1.76 million shs
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $21.11
• Consensus Rating: Moderate Buy

BridgeBio Oncology Therapeutics Stock Analysis - MarketRank™

BridgeBio Oncology Therapeutics scored higher than 73% of companies evaluated by MarketBeat, and ranked 176th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

BridgeBio Oncology Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on no strong buy ratings, 10 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

BridgeBio Oncology Therapeutics has a consensus price target of $21.11, representing about 684.8% upside from its current price of $2.69.

Amount of Analyst Coverage

BridgeBio Oncology Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for BridgeBio Oncology Therapeutics are expected to grow in the coming year, from ($2.81) to ($2.47) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of BridgeBio Oncology Therapeutics is -0.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BridgeBio Oncology Therapeutics is -0.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

BridgeBio Oncology Therapeutics has a P/B Ratio of 0.52. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.35% of the float of BridgeBio Oncology Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

BridgeBio Oncology Therapeutics has a short interest ratio ("days to cover") of 7.09.

Change versus previous month

Short interest in BridgeBio Oncology Therapeutics has recently increased by 13.97%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BridgeBio Oncology Therapeutics does not currently pay a dividend.

Dividend Growth

BridgeBio Oncology Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: N/A

News Sentiment

BridgeBio Oncology Therapeutics has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for BridgeBio Oncology Therapeutics this week, compared to 2 articles on an average week.

Search Interest

Only 2 people have searched for BBOT on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

MarketBeat Follows

2 people have added BridgeBio Oncology Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BridgeBio Oncology Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

24.40% of the stock of BridgeBio Oncology Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

54.89% of the stock of BridgeBio Oncology Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 10/27/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:BBOT
• CIK: 1869105
• Web: www.bridgebio.com
• Phone: (857) 702-0377
• Fax: N/A
• Employees: 88
• Year Founded: 2025

Price Target and Rating

• Average Price Target for BridgeBio Oncology Therapeutics: $21.11
• High Price Target: $29.00
• Low Price Target: $13.00
• Potential Upside/Downside: +684.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.82
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: 60,612,000
• Market Cap: N/A
• Optionable: N/A
• Beta: N/A